Form 4: INDP Director Sells Significant Preferred Stock Holdings

Indaptus Therapeutics Director David E. Lazar sold a substantial portion of his Series AA and Series AAA Preferred Stock holdings, convertible into millions of common shares.

Summary

• David E. Lazar, a Director and 10% Owner of Indaptus Therapeutics, Inc. (INDP), sold a significant portion of his preferred stock holdings.
• The transaction involved the sale of all 700,000 shares of Series AAA Preferred Stock, which are convertible into an aggregate of 105,000,000 shares of common stock.
• Additionally, 196,800 shares of Series AA Preferred Stock, convertible into an aggregate of 3,936,000 shares of common stock, were sold.
• The sales were executed under a Securities Purchase Agreement entered into on March 19, 2026, with the closing of the transaction occurring on March 23, 2026.
• Following the transaction, Mr. Lazar retains 103,200 shares of Series AA Preferred Stock, convertible into an aggregate of 2,064,000 shares of common stock.
• Both Series AA and Series AAA Preferred Stock are convertible at the option of the holder for no additional consideration and are perpetual, having no expiration date.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative event due to the significant reduction in beneficial ownership by a key insider, which could signal reduced confidence or create negative market sentiment, despite being a pre-planned transaction.

Positives

• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned sale rather than an immediate reaction to new information.

Negatives

• A Director and 10% owner significantly reduced their beneficial ownership in the company, selling preferred stock convertible into a total of 108,936,000 common shares.
• Such a large sale by an insider, especially a 10% owner, could be perceived negatively by the market, potentially signaling a lack of confidence or a need for liquidity.

Risks

• Potential negative market perception due to a significant insider sale, which could lead to downward pressure on the stock price.
• Reduced alignment of interests between the reporting person (Director and 10% owner) and other shareholders due to decreased ownership.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider sales, particularly by significant shareholders and directors, are closely watched by the market as they can sometimes signal a change in the insider's view of the company's future prospects or personal liquidity needs. While this sale was pre-planned under Rule 10b5-1(c), the sheer volume of shares involved for a biotech company like Indaptus Therapeutics could still draw investor scrutiny.

Comparison to Industry Standards

• Insider sales are common across all industries. However, a sale of preferred stock convertible into over 100 million common shares by a director and 10% owner in a biotech company like Indaptus Therapeutics, which often relies on investor confidence for funding and valuation, is a substantial event.
• For context, similar large insider sales in other small-cap biotech firms have sometimes preceded periods of stock price volatility or increased investor uncertainty, especially if not accompanied by clear explanations for the sale.

Stakeholder Impact

• Shareholders may experience negative sentiment and potential downward pressure on stock price due to the significant insider sale.
• The remaining board members and management may face questions regarding the insider's rationale for the sale.

Next Steps

• Investors will likely monitor future insider transactions and company announcements for any further insights into the rationale behind this significant sale.

Key Dates

Recommendation

The significant reduction in beneficial ownership by a Director and 10% owner, involving preferred stock convertible into over 100 million common shares, is a strong negative signal. While executed under a 10b5-1 plan, the sheer scale of the divestment by a key insider suggests a potential lack of confidence or a strategic shift that could weigh heavily on investor sentiment and the stock's future performance. This action warrants a cautious approach, suggesting a 'sell' recommendation for investors to mitigate potential downside risk.

Keywords

Indaptus Therapeutics, INDP, David E. Lazar, Form 4, insider trading, beneficial ownership, preferred stock, common stock, stock sale, director, 10% owner, SEC filing